官方認證

官方認證

NCCN^®
	OncotypeDX® 安可待®乳癌腫瘤基因檢測被NCCN 醫療指南評價為首選 "Preferred"的多基因檢測，能夠為雌激素受體陽性及 HER2陰性乳癌患者提供化療獲益的預測。¹ 了解更多完整版下載 >

IQWiG
	IQWiG (德國聯邦衞生部醫療質量與效率研究所)於TAILORx報告結果得出， OncotypeDX 安可待乳癌腫瘤基因檢測有足夠證據來指導早期入侵性、淋巴結呈陰性乳癌患者的輔助化療決策。² 完整版下載 >

NICE
	英國國家健康與臨床卓越研究院 (NICE) 推薦OncotypeDX 安可待乳癌腫瘤基因檢測是唯一具成本效益的基因檢測，可為淋巴結陰性和微轉移性的早期乳癌患者作化療獲益的預測。³ 了解更多完整版下載 >

St. Gallen
	聖加侖 (St. Gallen) 國際乳癌醫療指南強烈推薦OncotypeDX 安可待乳癌腫瘤基因檢測及其TAILORx研究結果可用於對淋巴結陰性或淋巴結陽性的早期乳癌患者作輔助化療的決策指導。⁴ 完整版下載 >

ASCO^®
	基於TAILORx研究結果，可指導於臨界值上的乳癌患者(ER陽性及HER2陰性的淋巴結陰性患者) 作輔助化療的決策。⁵ 了解更多完整版下載 >

ESMO^®
	歐洲腫瘤學學會 (ESMO) 指出OncotypeDX 安可待乳癌腫瘤基因檢測可以補充病理學的評估，提供復發風險的訊息，同時評估病人能否從額外的化療獲益。⁶ 了解更多完整版下載 >

Reference:

NCCN Guidelines. 01.2019. Available at: Link
IQWiG Press Release, September 2018. Available at: Link
NICE 2018. Available at: Link
Burstein et al. Ann Oncol. 2019.
Andre et al. J Clin Oncol. 2019.
Cardoso et al. Ann Oncol. 2019.

American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; ASCO does not endorse any product or therapy.

NCCN is a registered trademark of the National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guideline, go to nccn.org.

IQWiG is a registered trademark of Institute for Quality and Efficiency in Health Care.

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health in England.

© 版權所有 2024 Jacobson Medical (HK) Ltd